Expertise: Neuroscience 45 results
Neuroscience
CNS Summit
Neuroscience
AES Annual Meeting
Neuroscience
ECNP Congress Munich
Neuroscience
16th European Epilepsy Congress
Neuroscience
AAIC
Psychedelic drug development is moving into a more consequential phase. Compounds such as MDMA, psilocybin, LSD, and other psychoactive agents continue to be explored for serious mental health conditions, including post-traumatic stress disorder, treatment-resistant depression, major depressive disorder, and substance...
Neuroscience
3 Shifts Reshaping Alzheimer’s Trial Execution
Alzheimer’s disease development is entering a new phase. With disease-modifying therapies making up a significant share of the 2025 AD pipeline, sponsors are navigating a trial landscape shaped by earlier intervention, biomarker-driven diagnosis, and growing complexity in patient identification and enrollment. ...
Parkinson’s disease is one of the fastest-growing neurological disorders worldwide, supported by a robust and diverse clinical research pipeline. As understanding of disease biology continues to advance, there is growing recognition that traditional trial designs and endpoints may not fully...